Who We Are
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of potential treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising biological pathways implicated in cancer generation or progression. The pipeline includes four investigational product candidates:
- Zilovertamab, a monoclonal antibody that inhibits the ROR1 protein expressed in multiple hematologic and solid malignancies, in Phase 2 development with a lead indication of mantle cell lymphoma (MCL)
- ONCT-216, a small molecule that inhibits ETS-family oncoproteins, which have been implicated in multiple hematological and solid malignancies, in Phase 2 development with a lead indication of Ewing sarcoma, a rare pediatric cancer
- ONCT-808, an autologous CAR-T cell therapy that targets ROR1, as a targeted treatment for patients with multiple hematologic and solid malignancies, currently in preclinical development
- ONCT-534, a Dual-Action Androgen Receptor Inhibitor (DAARI), as a targeted therapy for advanced prostate cancer resistant to available therapies, currently in preclinical development
Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.